An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy

HIV Medicine

Volumn 9, Issue 4, 2008, Pages 208-213

  Madge, S ^a   Smith, C J ^a   Lampe, F ^a   Sabin, C A ^a   Youle, M ^a   Johnson, M A ^a   Phillips, A N ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Audit; Prevalence; Resistance; Undetectable viral load

Indexed keywords

ANTIRETROVIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; FEMALE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL AUDIT; MENTAL HEALTH; MONOTHERAPY; PATIENT CARE; PATIENT COMPLIANCE; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; VIREMIA; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LONDON; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT FAILURE; VIRAL LOAD; VIREMIA;

EID: 41549169220     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00548.x     Document Type: Article

References (18)

1. Lundgren JD, Mocroft A. The impact of antiretroviral therapy on AIDS and survival. J HIV Ther 2006; 11: 36-38.
2. Lampe F, Smith C, Madge S et al. Success of HIV clinical care according to demographic group among sexually-infected patients in a routine clinic population, 1999 to 2004. Arch Intern Med 2007; 167: 692-698.
3. Moore RD, Keruly JC, Gebo KA, Lucas GM. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J Acquir Immune Defic Syndr 2005; 39: 195-198.
4. Sabin CA, Hill T, Lampe F et al. on behalf of the steering committee of the UK Collaborative HIV Cohort (UK CHIC) Study Group. Treatment exhaustion of highly active antiretroviral therapy among individuals infected with HIV in the United Kingdom: Multicentre cohort study. Br Med J 2005; 330: 695-698.
5. Deeks S. Antiretroviral treatment of HIV-infected adults. Br Med J 2006; 332: 1489.
6. Jensen-Fangel S, Pedersen L, Pedersen C et al. The effect of race/ ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients. Clin Infect Dis 2002; 25: 1541-1548.
7. Mocroft A, Madge S, Johnson AM et al. for the EuroSIDA Study Group. A comparison of exposure groups in the EuroSIDA study: Starting highly active antiretroviral therapy (HAART), response to HAART and survival. J Acquir Immune Defic Syndr 1999; 22: 369-378.
8. Lampe FC, Gatell JM, Staszewski S et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: A multicohort analysis 1996 to 2002. Arch Intern Med 2006; 166: 521-552.
9. Frater AJ, Dunn DT, Beardall AJ et al. Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy. AIDS 2002; 16: 1139-1146.
10. Nellen JF, Wit FW, de Wolf F, Jurriaans S, Lange JM, Prins JM. Virologic and immunologic response to highly active antiretroviral therapy in indigenous and non indigenous HIV-1-infected patients in the Netherlands. J Acquir Immune Defic Syndr 2004; 36: 943-950.
11. Van de Berg JB, Hak E, Vervoort SCJM et al. Increased risk of early virological failure in non-European HIV-1-infected patients in a Dutch cohort on highly active antiretroviral therapy. HIV Med 2005; 6: 299-306.
12. Lee R, Monteiro EF. Third regional audit of antiretroviral prescribing in HIV patients. Int J STD AIDS 2003; 14: 58-60.
13. Curtis H, Sabin CA, Johnson MA, British HIV Association Clinical Audit Committee. Findings from the first national clinical audit of treatment for people with HIV. HIV Med 2003; 4: 11-17.
14. Martin JC, Soriano V, Jimenez-Nacher I, Martinez P, Gonzalez-Lahoz J. Overall trends in CD4 counts and plasma viraemia in an urban clinic since the introduction of highly active antiretroviral therapies. Clin Microbiol Infect 2001; 7: 678-681.
15. Rodriguez-Arenas MA, Jarrin I, Del Amo J et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses 2006; 22: 715-723.
16. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK, Panel on Clinical Practices for Treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002; 137: 381-433.
17. Cramer J. A systematic review of adherence with medications for diabetes. Diab Care 2004; 27: 1218-1224.
18. Kalsekar ID, Mahaven SS, Amonkar MM et al. Depression in patients with type 2 diabetes: Impact on adherence to oral hypoglycemic agents. Ann Pharmacother 2006; 40: 605-611.